Divi's Laboratories — Q3 FY26
Divis Laboratories reported Q3 FY26 consolidated total income of INR 2,692 crore, up 12% YoY, driven by strong custom synthesis (57% mix) and stable generics volume.
bullish
medium
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
46%Questions answered5Evaded / deflected12Questions audited
Evasive
High priority
Update on GLP-1 capacity buildup and pilot plant commercialization.
Asked by Surya Narayan Patra, PhillipCapital
Management declined to quantify capacity, citing confidentiality.
refused to give capacity numberscited confidentiality
Read the exchange
Question
So what is the capacity buildup that we are doing? Can you give some update on that front further?
Kiran S. Divi, Whole-Time Director and CEO
We have already completed construction of a pilot plant. We have also completed one of our commercial buildings... I'm not at the liberty to speak about capacity created, but the validations are going on as we speak.
Evasive
High priority
Are the three dedicated CS facilities related to peptides?
Asked by Surya Narayan Patra, PhillipCapital
Management refused to confirm if facilities are for peptides, gave generic answer.
refused to confirmvague answer
Read the exchange
Question
The three dedicated custom synthesis facilities... any of those are relating to peptides?
Kiran S. Divi, Whole-Time Director and CEO
I cannot comment on that, but what I can tell you is it's a mixture of everything. It's also in chemistry.
Partial answer
Medium priority
Capacity utilization and progress on contrast media opportunities.
Asked by Surya Narayan Patra, PhillipCapital
Gave overall utilization but not specific to contrast media or capacity details.
no specific capacity numbers for contrast media
Read the exchange
Question
What is the capacity that we would be having or at what utilization that we would be operating at? Any progress on the kind of newer opportunities?
Kiran S. Divi, Whole-Time Director and CEO
Capacity utilization, we are about 70%-80% of capacity utilization right now... validations are taking place... once the validations are done... it will go into commercialization.
Answered
Medium priority
Are the molecules going commercial due to inventory buildup by innovator?
Asked by Tushar Manudhane, Motilal Oswal Financial Services
Management clarified it's not inventory buildup but awaiting approvals.
Read the exchange
Question
Is it more like the inventory buildup by the innovator... if you could throw some light on this aspect?
Kiran S. Divi, Whole-Time Director and CEO
Once the validations are completed... we are waiting for all regulatory approvals, after which the volumes would be discussed for commercialization. I did not mention that I'm building up stock.
Partial answer
High priority
Timeline for commercial volumes from CS segment.
Asked by Tushar Manudhane, Motilal Oswal Financial Services
Agreed broadly but said timeline varies by product, no specific commitment.
timeline depends on productno firm date
Read the exchange
Question
So effectively, second half FY27, as a broad timeline to understand the business prospects from this. Is that correct understanding?
Kiran S. Divi, Whole-Time Director and CEO
Yes. So it depends on product to product... Some we already completed validations in this quarter... based on whenever it is being completed, we will immediately supply...
Answered
Medium priority
Hedging policy for export exposure.
Asked by Tushar Manudhane, Motilal Oswal Financial Services
Clearly stated no hedging currently, evaluating.
Read the exchange
Question
On the hedging policy, if you could throw light like how much of the business exposure we hedge or we don't hedge any of the exports?
Nilima Divi, Whole-Time Director Commercial
We are not hedging. We are evaluating at this point based on the overall scenario in the market.
Answered
Medium priority
Why limited growth in generic API despite stable raw materials?
Asked by Tushar Manudhane, Motilal Oswal Financial Services
Explained volume growth but value suppressed by pricing pressure.
Read the exchange
Question
What is stopping us from the growth in the generic space?
Nilima Divi, Whole-Time Director Commercial
The generic space, the pricing pressures are still continuing... As a volume, we have had a good growth. But it's just that because of the pricing pressures, value-wise, it doesn't reflect.
Partial answer
High priority
Drivers of sharp gross margin improvement in Q3.
Asked by Kunal Dhamesha, Macquarie
Attributed to product mix but did not quantify or explain QoQ change.
attributed to mix but no specificsdeferred to nine-month view
Read the exchange
Question
There is a sharp improvement on both year-over-year as well as quarter-over-quarter basis in quarter three. If you could highlight the drivers of this improvement.
Nilima Divi, Whole-Time Director Commercial
It's mainly based on the product mix. As you can see, the CS has improved in the nine-month period as compared to the previous nine months.
Declined
High priority
Proportion of molecules commercializing next year that are already approved vs new.
Asked by Kunal Dhamesha, Macquarie
Refused to answer due to confidentiality agreements.
cited confidentialityrefused to answer
Read the exchange
Question
What proportion of these molecules would be already approved for the innovators, and they would be adding us as an additional source?
Kiran S. Divi, Whole-Time Director and CEO
I'm sorry. I cannot answer this question because we are bound by CDA. I cannot disclose their plans.
Answered
High priority
Timeline for commissioning of dedicated CapEx announced in 2024.
Asked by Neha Manpuria, BofA
Gave a clear timeline of 2027 for commercialization.
Read the exchange
Question
When should we expect commissioning of that capacity and probably inspections or whatever regulatory approvals are required?
Kiran S. Divi, Whole-Time Director and CEO
By 2027, we should start seeing commercialization post our customers they start approving the product.
Evasive
Medium priority
Impact of China's export rebate withdrawal on Divi's portfolio.
Asked by Neha Manpuria, BofA
Corrected that it's about procurement, not sales, and did not give percentage impact.
corrected the premisedid not quantify impact
Read the exchange
Question
What percentage of our portfolio is getting impacted because of these rebates being moved?
Nilima Divi, Whole-Time Director Commercial
I didn't mention that with respect to the APIs. I said with respect to procurement of materials... we have increased our domestic supplier base to 78% of the procurement.
Evasive
High priority
Will the peptide building be sufficient for 4-5 years demand?
Asked by Vivek Agarwal, Citi
Declined to answer whether capacity is sufficient, citing confidentiality.
refused to discuss capacity adequacycited confidentiality
Read the exchange
Question
Will that be good enough to cater the customer demand for next 4-5 years, or is there any possibility that you may need to expand the capacities?
Kiran S. Divi, Whole-Time Director and CEO
For this customer, what we have dedicated, it is based on what his requirement and his designs are. I'm not at any other liberty to discuss on that.